Takeda Announces European Commission Approves ADCETRIS For The Treatment Of Adult Patients With Previously Untreated CD30+ Stage III Hodgkin Lymphoma In Combination With AVD
Portfolio Pulse from Happy Mohamed
Takeda Pharmaceutical Company Limited (TAK) has announced that the European Commission has approved ADCETRIS for the treatment of adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma. The approval is based on positive overall survival results from the Phase 3 ECHELON-1 study. This marks the first significant improvement in overall survival in two decades in Stage III & IV Hodgkin lymphoma. ADCETRIS is being jointly developed by Seagen (SGEN) and Takeda.
October 18, 2023 | 8:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seagen, which is jointly developing ADCETRIS with Takeda, could also benefit from the European Commission's approval of the drug for treating Stage III Hodgkin lymphoma.
As a co-developer of ADCETRIS, Seagen stands to benefit from the expanded approval of the drug. This could lead to increased revenues for Seagen and have a positive impact on its stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Takeda's ADCETRIS has received approval from the European Commission for treating Stage III Hodgkin lymphoma, expanding its current indications in the European Union. This could potentially increase Takeda's market share and revenues.
The approval of ADCETRIS for a new indication expands its market potential and could lead to increased sales and revenues for Takeda. This is likely to have a positive impact on Takeda's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100